Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Income from Continuing Operations (2018 - 2025)

Neurogene's Income from Continuing Operations history spans 6 years, with the latest figure at 24857000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 26.46% year-over-year to 24857000.0; the TTM value through Dec 2025 reached 91978000.0, down 23.36%, while the annual FY2025 figure was 91786000.0, 21.24% down from the prior year.
  • Income from Continuing Operations reached 24857000.0 in Q4 2025 per NGNE's latest filing, down from 21101000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11856000.0 in Q2 2023 to a low of 24857000.0 in Q4 2025.
  • Average Income from Continuing Operations over 3 years is 18265250.0, with a median of 18879500.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: plummeted 52.69% in 2024, then decreased 3.74% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 13953000.0 in 2023, then tumbled by 40.87% to 19656000.0 in 2024, then fell by 26.46% to 24857000.0 in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Income from Continuing Operations are 24857000.0 (Q4 2025), 21101000.0 (Q3 2025), and 23227000.0 (Q2 2025).